Cholesterol catalyses Aβ42 aggregation through a heterogeneous nucleation pathway in the presence of lipid membranes. by Habchi, Johnny et al.
 1
Cholesterol catalyses Aβ42 aggregation through  
a heterogeneous nucleation pathway  
in the presence of lipid membranes 
 
Johnny Habchi1*, Sean Chia1*, Céline Galvagnion1#*, Thomas C. T. Michaels1, 
Mathias M. J. Bellaiche1,2, Francesco Simone Ruggeri1, Michele Sanguanini1,  
Ilaria Idini4, Janet R. Kumita1, Emma Sparr3, Sara Linse4,  
Christopher M. Dobson1, Tuomas P. J. Knowles1,5, Michele Vendruscolo1+ 
 
 
1Department of Chemistry, University of Cambridge, Cambridge CB2 1EW, UK 
2Laboratory of Chemical Physics, National Institute of Diabetes and Digestive 
and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA 
3Division of Physical Chemistry, Department of Chemistry, Lund University, 
P.O. Box 124, 22100, Lund, Sweden 
4Department of Biochemistry & Structural Biology, Center for Molecular Protein 
Science, Lund University, P.O. Box 124, 221 00 Lund, Sweden 
5Department of Physics, Cavendish Laboratory, 19 J J Thomson Avenue, 
Cambridge CB3 0HE, UK 
#Present address: German Center for Neurodegenerative Diseases (DZNE), 
Sigmund-Freud-Strasse 27, D-53127, Bonn, Germany 
 
*Equal contributions 
+Corresponding author: mv245@cam.ac.uk 
 
Keywords 
Alzheimer’s disease, amyloid-β peptide; protein misfolding; protein aggregation; 
chemical kinetics; cholesterol; lipid vesicles; amyloid; heterogeneous nucleation 
 
Abbreviations 
AD, Alzheimer’s disease; Aβ, amyloid-β peptide; Aβ42, 42-residue form of Aβ; ThT, 
thioflavin T; DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine. 
 2
Alzheimer’s disease (AD) is a neurodegenerative disorder associated with the 
aberrant aggregation of the amyloid-β peptide (Aβ). Although increasing 
evidence implicates cholesterol in AD pathogenesis, the detailed mechanistic 
link between this lipid molecule and the disease process remains to be fully 
established. To address this problem, we adopt a kinetics-based strategy that 
reveals a specific catalytic role of cholesterol in the aggregation of Aβ42 (the 
42-residue form of Aβ). More specifically, we demonstrate that lipid membranes 
containing cholesterol promote Aβ42 aggregation by enhancing by up to 20-
fold its primary nucleation rate through a heterogeneous nucleation pathway. 
We further show that this process occurs as a result of the cooperativity in the 
interaction of multiple cholesterol molecules with Aβ42. These results identify 
a specific microscopic pathway by which cholesterol dramatically enhances 
the onset of Aβ42 aggregation, thereby rationalising the link between AD and 
increased levels of cholesterol in cell membranes.  
 
Over 40 million people currently suffer from AD worldwide, and as the global 
population ages, this number could approach 140 million by 20501. The deposition of 
Aβ into insoluble aggregates in brain tissue represents the molecular signature of the 
disease, with Aβ42, the 42-residue form of Aβ, being the major component of the 
deposits2–5. Therefore, understanding at the molecular level the effects of intrinsic 
and extrinsic factors on the aggregation process of Aβ42 is vital for developing 
effective therapeutic strategies aimed at inhibiting its self-assembly6,7. 
 
Among such factors, the disruption of lipid homeostasis in the brain is strongly 
associated with AD pathogenesis8,9. Lipids are found ubiquitously within the amyloid 
deposits formed by Aβ42 aggregates10. It has also been suggested that the 
comparative analysis of the lipid composition of the plasma and cerebrospinal fluid 
(CSF) of AD patients and healthy controls could lead to the identification of effective 
disease biomarkers and prognostic indicators of AD therapies9,10.  
 
A critical role of lipids in AD is consistent with the fact that the ε4 allele of the 
apoliprotein E gene (APOE) is the greatest currently known genetic risk factor for 
late-onset AD11,12. Apoliprotein E is a crucial regulator of cholesterol metabolism in 
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the brain and of triglyceride metabolism throughout the body13, and studies have 
shown that Aβ deposits fail to form in APOE knockout mice14. Therefore, much 
attention has been devoted to the link between AD and cholesterol. Recent studies 
have suggested that plasma cholesterol levels are about 10% higher in AD patients 
when compared to healthy individuals15, and that cholesterol accumulates in senile 
plaques of AD patients and in mouse models of AD10,16. Furthermore, it has also 
been suggested that statins, which are used to prevent cardiovascular diseases by 
lowering cholesterol levels, could also potentially reduce the risk of AD17. Brain 
cholesterol, which exists primarily (>99.5%) in a non-esterified state, is largely formed 
in the myelin sheaths and cellular membranes of glial cells and neurons18, represents 
about 25% of the total amount of cholesterol in the human body, and is important for 
neuronal development, synaptic plasticity, and brain function. The impairment of 
cholesterol homeostasis could therefore be an important factor in AD pathogenesis19.  
 
The mechanistic processes underlying the association of cholesterol with AD remain, 
however, to be fully established20,21. Evidence for a possible causative role is 
provided by recent studies showing that modulating cholesterol levels can regulate 
Aβ aggregation34,35. For example, depleting cholesterol in hippocampal neurons in 
AD animal models has been found to reduce Aβ42 aggregate levels,  while 
increasing it leads to their increase22. Additionally, lipid rafts, which are domains in 
cellular membranes enriched in cholesterol and sphingolipids, have been implicated 
in the processing of the amyloid precursor protein (APP) through which Aβ is 
generated9,10,23. Moreover, the region of residues 22-35 in the Aβ sequence has been 
identified as a potential binding site of cholesterol21. 
 
Although an interaction between Aβ42 and cholesterol has already been reported24, 
the mechanisms by which it occurs and affects Aβ42 aggregation have not yet been 
fully identified. For instance, the reduction in the rate of Aβ42 aggregation observed 
in the presence of dipalmitoylphosphatidylcholine (DPPC) gel phase membranes25, 
was abolished upon addition of cholesterol to form liquid ordered bilayer 
membranes25. On the other hand, other studies suggested that cholesterol can inhibit 
interactions between Aβ and lipid membranes, thus increasing the extracellular levels 
of Aβ and promoting its aggregation26.  
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In order to investigate this problem, here we analyse quantitatively the direct effects 
of cholesterol on Aβ42 aggregation using the strategy illustrated in Fig. 1. Our 
approach exploits the recent development of highly reproducible thioflavin-T (ThT)-
based kinetic measurements and of analytical approaches to their intepretations27,28. 
Such measurements have made it possible to show that the aggregation of Aβ42 is 
characterised by a surface-catalysed secondary nucleation mechanism, whereby the 
fibril surfaces act as catalytic sites for the generation of toxic Aβ42 oligomers. The 
oligomers thus generated can grow further and convert into fibrils, promoting the 
formation of additional toxic species in a highly effective catalytic cycle28–34.  
 
The analysis of the reaction kinetics has been powerful also in characterising the 
effects of intrinsic and extrinsic factors on the rates of individual microscopic steps in 
the aggregation process of the Aβ42 peptide35–39. In particular, the diverse pathways 
through which macromolecules, such as molecular chaperones and antibodies, can 
affect the aggregation of the Aβ42 peptide have recently been described in detail35–
37,40. Moreover, using the same approach, the effects of disease-associated 
mutations and pH variations could be deciphered, showing that both factors can give 
rise to enhancements in the secondary nucleation process of Aβ42 aggregation32. It 
has also been shown that the effects of small molecules on the different microscopic 
steps of the Aβ42 aggregation process can also be monitored in detail, thus leading 
to the development of a chemical kinetics-based drug discovery strategy that aims at 
identifying drug candidates that can inhibit specific steps in Aβ42 aggregation41,42.  
 
In the present study, we extend this kinetics-based strategy to decipher the role of 
cholesterol in modulating Aβ42 aggregation. To this end, we characterise at the 
molecular level the effects of vesicles prepared with 1,2-dimyristoyl-sn-glycero-3-
phosphocholine and cholesterol (DMPC:cholesterol vesicles) on the microscopic 
steps of Aβ42 aggregation (Fig. 1). Our results indicate that these vesicles provide a 
model membrane that can effectively increase the nucleation rate of Aβ42. 
Furthermore, we show that despite the occurrence of a cholesterol-dependent 
nucleation process, surface-catalysed secondary nucleation remains the dominant 
mechanism for aggregate proliferation, as in the lipid-free aggregation process. We 
then provide evidence that primary oligomers of Aβ42, whether they are formed 
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through homogeneous or heterogeneous nucleation events, are likely to possess 
structural similarities by showing that a previously characterised inhibitor of the 
homogeneous nucleation of Aβ42 aggregation also inhibits the heterogeneous 
primary nucleation events catalysed by lipid vesicles41.  
 
Overall, these results reveal a self-assembly process that includes a heterogeneous 
primary nucleation step through which Aβ42 aggregates in the presence of 
DMPC:cholesterol vesicles. This step can be significantly faster than that of the 
homogeneous primary nucleation, leading to the more rapid formation of potentially 
neurotoxic Aβ42 oligomers. We have therefore proposed a mechanism to explain 
how the presence of cholesterol can accelerate Aβ42 aggregation, thus enhancing 
our understanding of the molecular origins of AD and helping the development of 





Cholesterol-containing lipid vesicles accelerate Aβ42 aggregation. To decipher 
the role of cholesterol in Aβ42 aggregation, we carried out a global kinetic analysis of 
Aβ42 aggregation27 in the presence of zwitterionic vesicles containing cholesterol at 
concentrations ranging from 0 to 40 mol% of the total lipid concentration (Fig. 2 and 
Supplementary Figs. 1-4). We investigated this range because cholesterol accounts 
form about 20% of the total content of brain lipids, although its levels in neuronal 
membranes can vary substantially from one cell or organelle to another43,44. Thus, for 
example, the outer monolayer of plasma membranes have cholesterol levels of 
around 30 mol%, while they are much lower in the corresponding inner monolayer45.  
 
Since phosphatidylcholine (PC) lipids, together with phosphatidylethanolamine (PE) 
and phosphatidylserine (PS) lipids, constitute the most abundant components of 
neuronal membranes46, we investigated the effects of cholesterol on Aβ42 
aggregation for a series of model systems composed of zwitterionic PC lipids with 
different acyl-chain compositions in terms of the length and degree of unsaturation 
(DMPC (2 chains C14:0), POPC (C18:1 & C16:0) and DOPC (2 chains C18:1)). We 
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found that the level of unsaturation alters to different extents the effects of cholesterol 
on Aβ42 aggregation, with the rate of aggregation increasing with the degree of 
unsaturation of the PC hydrocarbon chain (DOPC>POPC>DMPC) (Supplementary 
Figs. 1 and 4). These findings may be explained by the increased exposure to 
hydrophobic hydrocarbon layer of the bilayer for the unsaturated lipids with bulky 
hydrocarbon chains, as the average accessible area per PC headgroup in the bilayer 
varies from 60 Å2 for DMPC to 69 Å2 for POPC and 72 Å2 for DOPC47,48. By contrast, 
although anionic lipids, such as PS, can influence significantly Aβ42 aggregation and 
the structure of the aggregates49,50, they are mainly found in the inner leaflet of the 
plasma membrane, and therefore are not enriched in the regions where cholesterol is 
primarily located.  
 
Therefore, to assess specifically the effects of cholesterol on the aggregation of Aβ42 
systematically in a physiologically relevant system, we used model systems 
composed of DMPC and cholesterol, which capture several important features of the 
behaviour of cholesterol in membranes highly relevant to lipid rafts51, including the 
formation of small scale domains and of the liquid ordered membrane structure52–54. 
The advantage of these model systems is that DMPC alone does not significantly 
influence Aβ42 aggregation (Supplementary Fig. 1), making it possible to identify 
clearly the effects of the added cholesterol.  
 
Using DMPC:cholesterol vesicles, we found that increasing cholesterol content 
significantly enhanced Aβ42 aggregation (Fig. 2 and Supplementary Figs. 1-3). 
These results also show that the effect of the lipid vesicles on the aggregation 
behaviour depends on both the lipid-to-protein (L/P) ratio (mol:mol) (Fig. 2b) and the 
cholesterol content within the membrane (Fig. 2c). We also observed a similar 
behaviour when we added cholesterol to model membranes composed of DMPC and 
DMPE, further supporting the conclusion that the presence of cholesterol promotes 
Aβ42 aggregation (Supplementary Fig. 5)55,56. Moreover, we observed a broadening 
of the DMPC melting transition and an increase in the size and fluidity of the DMPC 
vesicles with increasing concentrations of cholesterol (Supplementary Figs. 6 and 
7)57,58. In addition, the acceleration of the aggregation kinetics of Aβ42 was not 
directly related to an increase in the size of the vesicles (Supplementary Fig. 8). 
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A maximum effect corresponding to a decrease by about 35-40% of the half time of 
the aggregation reaction was observed at [L]/[P] ratios above 200 for vesicles 
containing 5% and 10% cholesterol (Fig. 2b). For all [L]/[P] ratios, the acceleration in 
the aggregation kinetics of Aβ42 shows a strong dependence on the membrane 
composition up to a cholesterol content of about 15 mol%; the acceleration appears 
to be unaffected by further increases (Fig. 2 and Supplementary Figs. 1-3). This 
non-linear response of the aggregation kinetics suggests that specific changes in the 
membrane properties are crucial to the aggregation process59,60. These results can 
be rationalised by observing that in a PC lipid system at 37 oC, a single liquid 
disordered (ld) phase is present at cholesterol contents below 15%. The cholesterol 
molecules are homogenously solubilized in the bilayer, gradually changing its 
properties and composition with increasing cholesterol contents (Fig. 2c). When the 
cholesterol content exceeded 15 mol%, the system segregated into small-scale 
domains (“rafts”) composed of ld and liquid ordered (lo) phases. At a cholesterol 
content above 30 mol%, however, a single lo was formed, and over the whole range 
of domain formation, the compositions in the segregated ld and lo domains were 
unchanged and determined by the compositions at the phase boundaries, with the 
proportions of the different domains varying with cholesterol content.  
 
To exclude possible interferences of the lipid vesicles with the ThT fluorescence 
signal, Aβ42 aggregation was also monitored by circular dichroism (CD) 
spectroscopy (Supplementary Fig. 9)61. We recorded time-dependent CD spectra of 
a 20 μM Aβ42 solution in the absence or presence of DMPC vesicles with either 0% 
or 15% cholesterol at a [L]/[P] ratio of 10 (Supplementary Fig. 9). At time 0, the CD 
spectrum of Aβ42 was characterised by a negative mean residue ellipticity (MRE) at 
about 200 nm, which is characteristic of an unfolded peptide. At the end of the 
reaction, however, the spectrum exhibited positive and negative MRE values at about 
200 nm and 218 nm, characteristic of β-sheet structure. The time dependence of the 
MRE values at 218 nm (MRE218nm) in the presence of vesicles at a [L]/[P] ratio of 10 
shows that β-sheet formation occurs at a slightly slower rate in the presence of 
DMPC vesicles than in its absence (Supplementary Fig. 9). This difference could 
arise from the multiple general contributions of foreign surfaces provided by both the 
cuvette and the lipid, which can affect the aggregation process62. By comparing the 
 8
spectra over time in the presence of DMPC:cholesterol vesicles containing 15% 
cholesterol, and in the presence of vesicles free of cholesterol, where general 
additional contributions from surface effects are similar, we observed that the 
formation of β-sheet structures of Aβ42 occurs more rapidly in the presence of 
DMPC:cholesterol vesicles, in agreement with the results obtained using ThT-based 
kinetics (Supplementary Fig. 9). 
 
 
Morphology and structure of Aβ42 fibrils in the presence of cholesterol-
containing lipid vesicles. Using atomic force microscopy (AFM) we acquired high-
resolution 3D morphology maps of Aβ42 fibrils formed in the absence and in the 
presence of DMPC vesicles, the latter both free of cholesterol or containing 15% 
cholesterol at a [L]/[P] ratio of 10 (Fig. 3a)63. No significant differences in the length 
and height of the fibrils could be observed between the samples. Also, by using cryo-
electron microscopy (cryo-EM), we found that fibrils formed in the presence of 
vesicles with 15% cholesterol (Fig. 3b,c) are of similar length and thickness as those 
formed of Aβ42 alone (Fig. 3d,e). However, the fibrils appeared to be organised 
slightly differently, implying that they could have altered surface properties. Previous 
observations of the presence of lipids in amyloid plaques10 suggest that lipids may be 
incorporated in the aggregates; indeed few vesicles are seen (Fig. 3b,c). To 
investigate further the structural organisation of the fibrillar aggregates, we used 
Fourier transform infrared (FTIR) spectroscopy (Fig. 3f and Supplementary Fig. 10). 
The IR absorption of proteins is characterised by a series of amide bands, with the 
shape and position of amide bands I providing information on their secondary and 
quaternary conformations64. We found identical amide I bands, and thus similar 
structural organization of the ThT-free Aβ42 fibrils within experimental errors, as also 
demonstrated by the comparison of their second derivatives (Fig. 3f and 
Supplementary Fig. 10). In addition, we carried out fluorescence measurements 
that showed that the spectra of ThT bound to Aβ42 fibrils are similar in the presence 
and absence of the cholesterol-containing lipid vesicles during fibril formation 
(Supplementary Fig. 10).  
 
 9
DMPC:cholesterol vesicles accelerate the rate of Aβ42 primary nucleation by 
up to 20-fold. We carried out a quantitative analysis of Aβ42 aggregation in the 
presence of lipid vesicles to define the changes in the rate constants governing each 
microscopic step. The analysis of tlag (the time required for ThT fluorescence to reach 
10% of the final value) and tgrowth (the time required for ThT fluorescence to reach 
90% of the final value after tlag) of Aβ42 aggregation shows that these vesicles have 
a concentration-dependent effect on tlag but no significant effect on tgrowth (Fig. 4a). 
These results indicate that the primary nucleation pathway is the main microscopic 
process perturbed by the presence of DMPC:cholesterol vesicles65,35. In addition, the 
scaling exponent of the Aβ42 concentration dependence, which reflects the 
dominance of the fibril-catalysed secondary nucleation process29, remained 
unaffected within error limits with a value close to -1.3 in the presence of these 
vesicles (Fig. 4b).  
 
We then carried out an additional series of measurements of the aggregation kinetics 
of Aβ42 under conditions where the surface-catalysed secondary nucleation was 
supressed by a molecular chaperone, the Brichos domain37 (Fig. 4c and 
Supplementary Fig. 11). Thus, in the presence of Brichos, Aβ42 aggregation is 
mainly driven by primary nucleation and elongation since surface-catalysed 
secondary nucleation is completely suppressed (Supplementary Fig. 11). We found 
that the aggregation kinetics of Aβ42 were significantly accelerated in the presence 
of DMPC:cholesterol vesicles, and to a much smaller extent when the vesicles are 
free of cholesterol (Fig. 4c). Thus, the observed effects can be attributed to an 
increase in the rates of primary nucleation and/or elongation when cholesterol is 
incorporated in the vesicles. 
 
Next, to define more quantitatively how cholesterol affects the microscopic rates, we 
modified the underlying kinetic equations (Eqs. 1 and 2) to account for the addition of 
a lipid-induced aggregation process to the three microscopic events (primary 
nucleation, surface-catalysed secondary nucleation and elongation) involved in the 
aggregation pathway of Aβ42. We analysed the aggregation profiles using these 
modified equations, which relate the macroscopic time evolution of the fibril mass to 
the rate constants of the different microscopic events. We found the best fit when the 
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rate of the primary pathway (k+kn) is significantly increased, while the secondary 
pathway (k+k2) was relatively unaffected (Fig. 4d-e). These results indicate that 
DMPC:cholesterol vesicles are mainly involved in enhancing the primary nucleation 
process, rather than the elongation process. Similar results were obtained for 
DMPC:cholesterol vesicles containing cholesterol levels as low as 5% 
(Supplementary Fig. 12).  Additionally, the best fit of the Aβ42 aggregation kinetics 
in the presence of Brichos and DMPC:cholesterol vesicles corresponds to an 
increase only in the rate of the primary nucleation, thus further confirming the role of 
DMPC:cholesterol vesicles in accelerating the primary processes in Aβ42 
aggregation (Supplementary Fig. 11).  
 
Taken together, these data indicate that the DMPC:cholesterol vesicles act as 
catalysts of Aβ42 aggregation by increasing the formation of primary oligomers 
thereby accelerating the overall aggregation kinetics. This cholesterol introduces 
heterogeneous primary nucleation as a new active process into the Aβ42 
aggregation pathway. Thus, the primary nucleation of Aβ42 occurs through two 
distinct mechanisms, a homogenous pathway (with rate constant kn) where new 
aggregates are formed solely from the interactions between soluble monomers, and 
a heterogeneous pathway where new aggregates are generated at a rate that 
depends on the concentrations of both monomeric Aβ42 and lipid vesicles (with rate 
constant kcat). Hence, the overall rate constant of Aβ42 primary nucleation becomes 
kn’, which accounts for the contribution of both kn and kcat (see Materials and 
Methods).  
 
Heterogeneous primary nucleation depends on the concentration of Aβ42 monomers 
and on the ratio of accessible sites, s, of the DMPC:cholesterol vesicles. Indeed, a 
steep linear increase with the [L]/[P] ratio in the primary pathways was observed for 
DMPC:cholesterol vesicles containing 10% cholesterol at a [L]/[P] ratios below 200 
(Fig. 4e). In the case of DMPC:cholesterol vesicles containing 5% cholesterol, 
saturation could not be observed even in the presence of [L]/[P] ratios as high as 400 
(Supplementary Fig. 12). In all cases, the heterogeneous primary nucleation was 
found to be linearly dependent on the [L]/[P] ratio, and consequently on the ratio of 
accessible sites, s, before saturation is reached (see Materials and Methods). At 
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high concentrations of accessible sites, i.e. at [L]/[P] ratios above 200 in the case of 
DMPC:cholesterol vesicles containing 10% cholesterol, where the heterogeneous 
primary nucleation is likely to be restricted by the adsorption and desorption rate of 
the peptide, the relative increase in the heterogeneous primary nucleation rate is 
maximal and corresponds to an increase by a factor of 20±2 (Fig. 4e). We next 
carried out a numerical estimate of the rate of the formation of the total mass of Aβ42 
aggregates in which we increased the rate of primary nucleation by 20-fold (Fig. 4f). 
In agreement with the results of all the experiments performed in the presence of 
sufficient amounts of cholesterol to achieve maximum rate of Aβ42 aggregation (Fig. 
4f, inset), we found that the theoretical half-time is smaller than that of Aβ42 alone 
by about 40% (Figs. 2b and 4f). A theoretical prediction based on the analytical 
solution for the aggregation kinetics66–68 indicates that an increase in the rate of 
primary nucleation of an aggregation reaction translates into a decrease of about 
1/log(20), i.e. 34%, in the reaction half-time, which is fully consistent with the 
experiments reported here (see Materials and Methods).  
 
Chemical kinetics characterise the roles of Aβ42 monomers and cholesterol in 
DMPC:cholesterol vesicles in the heterogeneous primary nucleation step. The 
relative acceleration, , of primary nucleation in Aβ42 aggregation due to the 
introduction of a lipid-associated heterogeneous pathway is dependent on the 
concentration of Aβ42 monomers, (0), as well as the accessibility factor,  , of the 
lipid system, which we found to be dependent on the proportion of cholesterol within 
the lipid membrane (Eq. 9). We thus set out to characterise in detail the contributions 
to the heterogeneous primary nucleation pathway of the various species involved, 
including the Aβ42 monomers and the fraction of cholesterol in DMPC:cholesterol 
vesicles. 
 
First, we observed that the total lipid concentration of the DMPC:cholesterol vesicles 
containing 10% cholesterol required for a maximum rate of Aβ42 aggregation was 
higher at increasing concentrations of Aβ42 (Supplementary Fig. 13). This 
observation implies that  decreases as the concentration of Aβ42 monomers 
decreases. Considering that  (Eq. 10) describes the relative increase of primary 
nucleation due to the additional heterogeneous primary nucleation per lipid surface 
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available for each peptide, a double logarithmic plot of  (0)  against the initial 
monomer concentration, (0), yields a line with slope nh, which corresponds to the 
monomer concentration dependency of the heterogeneous nucleation pathway (Fig. 
5a, Materials and Methods). The low reaction order observed for nh (nh < 2) 
suggests that, over the range of monomer concentrations probed in our experiments 
(1.5-3 μM), the coverage of a single nucleation site by monomers could be saturated, 
such that the heterogeneous nucleation pathway in this case is primarily dependent 
on the number of accessible sites for each peptide ([L]/[P]) (see Materials and 
Methods). 
 
As observed above, the maximum rate of Aβ42 aggregation occurred at different 
[L]/[P] ratios for the different cholesterol content of DMPC:cholesterol vesicles (Fig. 
2b,c and Supplementary Figs. 1-3). These effects were found to depend in a non-
linear manner on the cholesterol concentration, thus suggesting that the organisation 
of cholesterol within the DMPC:cholesterol membranes might be responsible for 
creating accessible catalytic sites, s, for Aβ42 nucleation. To explain these findings, 
we hypothesised that the relative increase of primary nucleation, , might be 
controlled by the presence of multiple cholesterol molecules. From the probability of 
observing m adjacent sites occupied by cholesterol molecules, p = θm, where θ 
denotes the surface coverage by cholesterol, i.e. the percentage of cholesterol within 
the membrane, we found for the accessibility factor,  ~ θm. To test this prediction, 
we plotted  as a function of θ in a log-log plot, finding a line with a slope of m > 1 
(Fig. 5b). This result indicates that the number of accessible catalytic surface sites is 
correlated with the higher order assembly of cholesterol molecules within the 
DMPC:cholesterol membrane. Therefore, under these conditions, at the maximal 
acceleration of Aβ42 aggregation, where the primary pathways are accelerated 20-
fold, assuming that the catalysis involves several molecules of cholesterol, the total 
number of catalytic sites is approximately 10% of the number of Aβ42 monomers 
(see Materials & Methods). These results imply the presence of a positive 
cooperativity in the interaction of Aβ42 with cholesterol-containing membranes, and 
further increases in the number of catalytic sites do not increase the aggregation 
rate. The total number of nucleation sites estimated in this way was found to be at 
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least two orders of magnitude higher than the number of nucleation sites required for 
a maximal effect to occur.  
 
We then explored whether or not Aβ42 oligomers formed as a result of 
heterogeneous primary nucleation possess similar structural features to those formed 
by homogeneous primary nucleation. Since primary nuclei are formed transiently 
during the aggregation process, their direct structural characterisation is very 
challenging6. We therefore assessed their structural properties using as a probe 
bexarotene, a small molecule that inhibits Aβ42 primary nucleation (Fig. 5c and 
Supplementary Fig. 14)41. We found that bexarotene inhibits Aβ42 primary 
nucleation irrespective of whether the primary oligomers of Aβ42 are formed through 
homogeneous or heterogeneous nucleation. These results suggest that the nuclei 
generated through homogeneous or heterogeneous primary nucleation share 
common structural features (Fig. 5c and Supplementary Fig. 14). 
 
We then estimated the total rate of formation of oligomers from both primary and 
secondary processes in the aggregation of a 2 μM solution of Aβ42 in the absence 
and presence of DMPC:cholesterol vesicles containing increasing concentrations of 
cholesterol (see Materials and Methods). We found that increasing the rate of 
primary nucleation increases the aggregation reaction rate without affecting 
significantly the total load of toxic oligomers generated during the reaction29,35–37,41,42. 
Consistently, our calculations show that accelerating Aβ42 primary nucleation in the 
presence of DMPC:cholesterol vesicles is accompanied by earlier formation of 





It is increasingly recognised that changes in lipid homeostasis can influence the 
levels of toxic species formed by Aβ42, as indicated by recent results both in cell 
cultures and in vivo22,69. Moreover, the kinetics of Aβ42 oligomerization and amyloid 
formation in vitro have been found to be affected by the presence of specific lipids 
including gangliosides and sphingomyelin70.  
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To rationalise these findings, we have identified here a mechanism by which a 
specific lipid involved in AD pathology influences the process of Aβ42 aggregation. 
We have thus shown that cholesterol-containing vesicles provide an alternative 
heterogeneous primary nucleation route that results in a faster rate of formation of 
oligomeric species. 
 
These results provide insights into the potential pathological role of Aβ42 in brain 
tissue. For typical cellular volumes (0.3-5 pL) and physiological levels of Aβ42 (1-10 
nM), based on Eq. 6, we can estimate that it would take on average between 10 and 
300 years for the Aβ42 aggregation process to occur spontaneously. We found, 
however, that the onset of Aβ42 aggregation is accelerated up to 20 times by the 
heterogeneous primary nucleation pathway created by DMPC:cholesterol vesicles, 
thus dramatically reducing the average nucleation times to the range of months to 
decades. Although these estimates are only indicative, as they do not reflect the 
complexity of the cellular environment, they illustrate how heterogeneous nucleation 
processes can substantially accelerate the formation of Aβ42 species (Fig. 6).  
 
Overall, our results indicate that while spontaneous Aβ42 aggregation may be a 
rather slow process, triggering it through heterogeneous nucleation pathways can 
increase substantially the rate of aggregation, suggesting that cholesterol, or other 
compounds with a similar effect on Aβ42 aggregation, could indirectly constitute a 
risk factor for AD. 
 
By describing a molecular mechanism through which DMPC:cholesterol vesicles 
promote Aβ42 aggregation, we have provided a possible explanation for the 
proposed link between increased levels of cholesterol and AD. These results have 
been obtained by applying a chemical kinetics approach that allowed us to dissect 
the overall macroscopic aggregation process of Aβ42 into its underlying component 
microscopic reactions. This strategy has led to the determination of the manner in 
which DMPC:cholesterol vesicles contribute to the early steps in Aβ42 aggregation 
by providing an alternative route for primary nucleation. The present work thus 
provides a clear example of the importance of understanding in detail the molecular 
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mechanisms in which physiological factors can trigger the aggregation of Aβ42 in the 
complex molecular environment of the brain. As we have shown these factors can 
dramatically reduce the typical timescale of Aβ42 aggregation, and thus their 
identification is crucial to understand the best points of intervention for strategies 






Theoretical analysis  
 
Kinetic analysis in the absence of lipids. The aggregation of Aβ42 involves a 
process where secondary nucleation is responsible for the generation of most of the 
aggregates29. The aggregate mass concentration, M(t), and the aggregate number 
concentration, P(t), can be described by the following differential equations31:  
 ( ) = ( ) + ( ) ( )       (Eq. 1) 
 ( ) = 2 ( ) ( )        (Eq. 2) 
 
where the initial concentration of soluble monomers is denoted by m(0), nc and n2 
describe the dependencies of the primary and secondary pathways on the monomer 
concentration, and kn, k+ and k2 are the rate constants of primary nucleation, 
elongation and surface-catalysed secondary nucleation, respectively. 
 
Using self-consistent methods, approximate analytical solutions to these differential 
equations can be obtained that describe the time evolution of the total fibril mass 
concentration, M(t), as29,30  
 
( )( ) = 1 −      (Eq. 3)  
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where (∞) = (0) is the final mass concentration of aggregates and        ± = ± ,    ± = ± ,   = ( ) + ,   = − 4  
    
with = 2 (0)  and = 2 (0) . 
 
Note that, according to Eq. 3, to capture the complete macroscopic assembly 
process, only two particular combinations of the rate constants are needed, namely 
k+kn and k+k2. These two particular combinations of microscopic rate constants define 
the intrinsic timescales associated with the proliferation of new aggregates through 
primary pathways, = 2 (0) , and through secondary pathways, =2 (0) , respectively. 
 
The experimental curves that are shown in Fig. 4c-d and Supplementary Fig. 12 
were fitted using Eq. 3 where we introduced perturbations to  and  in order to 
account for the inclusion of the lipid-surface catalysed process. This procedure is 
carried out by adding to the rate constants of each of the microscopic steps a new 
factor, x, that allows the description of the experimental curves in the presence of the 
lipids, i.e. k’ = k + x. It was found that the best fits were derived when the rate of 
primary pathways (k+kn) was significantly increased, and the rate of secondary 
pathways (k+k2) was relatively unaffected. Coupled with other experiments (Fig. 4a-
c) that support these fits, we observe that the lipid-catalysed process is mainly 
captured in the primary pathway, .  
 
Theoretical model for a lipid-catalysed heterogeneous primary nucleation. The 
presence of low amounts of DMPC:cholesterol vesicles introduces a new active 
process into the aggregation pathway of Aβ42, known as heterogeneous primary 
nucleation with the kcat rate constant:  
 ( ) = ( ) + ( ) + ( ) ( )    (Eq. 4) =   {[ ]/[ ]}          (Eq. 5) 
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where s denotes the ratio of accessible surface sites for heterogeneous primary 
nucleation, which is a function of the lipid-to-protein ratio, [L]/[P].   is the surface 
accessibility constant, and nh denotes the monomer concentration dependency of the 
heterogeneous nucleation pathway. It should be noted that the surface accessibility 
factor   is dependent on the lipid system. In this particular study, the parameter  is 
found to depend on the fraction of cholesterol in the DMPC:cholesterol membrane 
(Fig. 2b-c); in particular,   is much greater in the case of DMPC:cholesterol vesicles 
as compared to the cholesterol-free ones. We rationalise the heterogeneous 
nucleation mechanism through the assumptions of the Langmuir adsorption isotherm, 
which indicates that the available lipid vesicles provide a surface for adsorption of 
Aβ42.  This may facilitate nucleation and lead to the formation of Aβ42 primary 
oligomers on the surface of the DMPC:cholesterol vesicles.  
 
Generalising the self-consistent methods to the new kinetic equations, it is possible 
to obtain an approximate analytical solution for M(t) in the presence of the additional 
nucleation mechanism (Eq. 4) as 
 
( )( ) = 1 −     (Eq. 6)  
 
where (∞) = (0) as before and 
   ′± = ± ,    ′± = ± ,   ′ = ( ) + ,   ′ = ′ − 4 ′ ′ ′
     
with = = 2 (0)  and with a slight modification to , the primary 
pathway 
 ′ = 2 (0) + 2 (0)       (Eq. 7) 
 
Hence, the additional heterogeneous nucleation mechanism can be accounted for by 
a modification of the rate constant of primary nucleation, kn, to give an effective rate 
constant, kn’, that includes the heterogeneous nucleation pathway 
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  ′ = + (0)        (Eq. 8) 
 
In other words, the analytical solution in Eq. 6 is equivalent to Eq. 3 with a slight 
modification to  that accounts for the presence of the additional nucleation pathway. 
Hence, kinetic traces of aggregation in the presence of heterogeneous primary 
nucleation can be analysed simply by using Eq. 3 (the analytical solution in the 
absence of lipids), but the extracted combined parameter for the primary pathway, 
k+kn’, is interpreted, using Eq. 8, as an effective parameter that includes the effect 
from the heterogeneous nucleation step.  
 
Assuming that the homogeneous primary nucleation rate is unaffected by the 
introduction of the heterogeneous nucleation pathway, using Eq. 8, we can compute 
the (relative) acceleration =  of primary nucleation due to the presence of a 
heterogeneous pathway as 
 = = 1 +  ( ) [ ]/[ ]       (Eq. 9) 
 
and it is therefore dependent on the concentration of Aβ42. For a given lipid system 
where the accessibility factor, , is constant for various protein concentrations, the 
slope  of a plot of  vs the lipid-to-protein ratio [L]/[P] 
 
  =  ( )          (Eq. 10) 
 
can be used to determine the reaction order for the heterogeneous nucleation step, 
nh. Specifically, the slope of a double logarithmic plot of  (0)  against  (0) 
equals nh (Fig. 4a). The low reaction order observed for nh suggests that over the 
range of monomer concentrations probed in our experiments (1.5-3 μM), the 
coverage of monomers along a single nucleation site could be saturated. Specifically, 
we can model the rate of heterogeneous primary nucleation using a Langmuir 
adsorption isotherm model by replacing (0) by the monomer surface coverage 
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(0) = ( )( ) , where K is the equilibrium binding constant.  When the coverage 
of the nucleation sites by the monomers is large ( (0) >>> K), the Langmuir 
adsorption process is saturated, meaning that (0)  is independent of (0); 
hence, the saturation of surface nucleation sites could explain the observed low 
reaction order nh of the heterogeneous nucleation pathway with respect to the 
monomer concentration.  
 
In the presence of large number of accessible surface sites, the rate of 
heterogeneous primary nucleation is constrained by the availability of free Aβ42 
monomers that could adsorb to a surface nucleation site at any point of time, rather 
than by the lipid concentration, so the rate laws become: 
 ′ = +          (Eq. 11) 
 
where max =  , and 
 = 1 +          (Eq. 12) 
 
By taking the maximum increase of k+kn’/k+kn into account (Fig. 4f), we can conclude 
that the contribution of the heterogeneous primary nucleation increases the overall 
rate of primary nucleation by maximum 20-fold (Eq. 7). 
 
From the approximate analytical solution Eq. 3, t1/2 is found to occur at
66–68 
 
/ ≈ log ( )          (Eq. 13) 
 
Thus, if we consider solely an increase in the rate of primary nucleation, kn’ by 20 
times, , the primary nucleation pathway, would increase by approximately √20 
times. Correspondingly,  =  would increase by approximately 20 times, with no 
change in . Hence, the relative increase in t1/2 is estimated to be log(1/20) ≈ 34%.  
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Estimate of the number of nucleation sites. Under the assumption of random and 
independent packing of cholesterol molecules on the surface of lipid vesicles, the 
probability of finding m-tuples of occupied adjacent surface sites is: 
 =           (Eq. 14) 
 
where θ is the surface coverage by cholesterol, i.e. the fraction of surface sites 
covered by cholesterol molecules, that is the % of cholesterol within the membrane. 
Since =   {[ ]/[ ]}  (Eq. 5),  ~  θm.  
 
As we defined earlier (Eq. 10), the slope  of a plot of  vs lipid concentration [L] 
depends on both  and the concentration of a monomer. Thus, for a constant protein 
concentration of different lipid systems (DMPC with different proportions of 
cholesterol),  can be used to determine . Since  ~  θm, the slope of a double 
logarithmic plot of  against the % of cholesterol within the membrane, θ, we find that 
m ≈ 3 according to Fig. 5b. 
 
At given monomer and lipid concentrations, we can thus estimate the number of 
accessible surface nucleation sites per Aβ42 monomer 
 = { ( )[ ]}/ (0)        (Eq. 15) 
 
By taking the [L]/[P] ratio at which maximal acceleration of 2 μM Aβ42 aggregation is 
observed for the different cholesterol concentrations, the average rsites is found to be 










Data availability statement  




J.H., S.C., C.G., T.C.T.M., E.S., S.L., C.M.D., T.P.J.K., and M.V. designed research. 
J.H., S.C., C.G., F.S.R., M.S., I.I., performed research. J.H., S.C., C.G., F.S.R., I.I., 
J.R.K., E.S., S.L., C.M.D., T.P.J.K., and M.V. contributed reagents/analytic tools. 
J.H., S.C., C.G., T.C.T.M., M.M.J.B., F.S.R., E.S., S.L., C.M.D., T.P.J.K., and M.V. 
analysed the data. All authors discussed the results and contributed to the writing of 
the paper. J.H., S.C., and C.G. contributed equally to this work. Correspondence and 
requests for materials should be addressed to M.V.  
 
Conflict of interest 
The authors declare no conflict of interest. 
 
Acknowledgments 
We acknowledge support from the Centre for Misfolding Diseases (J.H., S.C., 
T.C.T.M., M.M.J.B., F.S.R., M.S., J.R.K., C.M.D., T.P.J.K., and M.V.); the Agency for 
Science, Technology and Research, Singapore (S.C.); the NIH-Oxford/Cambridge 
Scholars Program (M.M.J.B.); the Cambridge Commonwealth, European and 
International Trust (M.M.J.B.); the Frances and Augustus Newman Foundation 
(T.P.J.K.); the UK Biotechnology and Biochemical Sciences Research Council 
(C.M.D. and M.V.); and the Wellcome Trust (C.M.D., T.P.J.K., and M.V.). This work 
was supported by the Intramural Research Program of the National Institute of 







Figure 1. Schematic illustration of the strategy used in the present work. Aβ42 
aggregation kinetics were performed in the absence and the presence of DMPC lipid 
vesicles that were either free or contain different concentrations of cholesterol. 
Subsequently, the effect of the lipid vesicles was assessed at a microscopic step 
level.  
 
Figure 2: DMPC:cholesterol vesicles accelerate Aβ42 aggregation. (a) 
Comparison of the kinetic profiles for the aggregation of a 2 μM Aβ42 sample in the 
presence of either DMPC vesicles or DMPC:cholesterol vesicles containing 
increasing concentrations of cholesterol up to 15% at a [L]/[P] ratio of 50. (b) 
Evolution of normalised t1/2 of the aggregation kinetics of Aβ42 against [L]/[P] as 
derived from the data in Supplementary Fig. 1. (c) Evolution of normalised t1/2 of the 
aggregation kinetics of Aβ42 against the percentage of cholesterol within the 
membrane as derived from the data in Supplementary Figs. 1-3. Note the change of 
the DMPC membrane properties from a single liquid disordered phase (ld) to a liquid 
ordered phase (lo) in the presence of increasing concentrations of cholesterol. 
Throughout, error bars indicate standard deviation among independent replicates. 
 
Figure 3. Biophysical characterisation of the effects of DMPC:cholesterol 
vesicles on Aβ42 fibrils. (a) AFM images of ThT-free Aβ42 samples at time 0 h and 
after 12 h incubation at 37 °C in the absence or the presence of DMPC:cholesterol 
vesicles containing 0 or 15% cholesterol at [L]/[P] ratio of 10. Similar height 
distributions are observed for Aβ42 fibrils irrespective whether they are formed in the 
absence or the presence of lipid vesicles (see red and blue marks on the images). 
(b-e) Cryo-EM images of ThT-free Aβ42 fibrils. (b,c) are two representative images of 
Aβ42 fibrils formed in the absence of DMPC:cholesterol vesicles containing 15% 
cholesterol at [L]/[P] ratio of 10, while (d,e) are two representative images formed in 
their presence. White arrows indicate the presence of the DMPC:cholesterol vesicles. 
(f) Second derivative of the IR amplitude of Aβ42 fibrils formed in the absence or the 
presence of DMPC:cholesterol vesicles containing 0 or 15% cholesterol at [L]/[P] 
ratio of 10.  
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Figure 4. DMPC:cholesterol vesicles accelerate Aβ42 primary nucleation by up 
to 20-fold through a heterogeneous nucleation process. (a) Comparison of 
normalised tlag and tgrowth derived from the aggregation profiles of 2 μM Aβ42 in the 
presence of increasing concentrations of DMPC:cholesterol vesicles containing 10% 
cholesterol as a function of the [L]/[P] ratio (see Supplementary Fig. 1). (b) Half-
time, t1/2, of Aβ42 aggregation as a function of the initial Aβ42 monomer 
concentration in the absence or presence of DMPC:cholesterol vesicles containing 
10% cholesterol at [L]/[P] ratios of 50 and 200. (c) Kinetic profiles of the aggregation 
reaction of 1.2 μM Aβ42 in the presence of one molar equivalent of Brichos (1.2 μM), 
and DMPC or DMPC:cholesterol vesicles containing 10% cholesterol at [L]/[P] ratios 
of 50 and 100. (d) Aggregation profiles of 2 μM Aβ42 in the absence and presence of 
DMPC:cholesterol vesicles containing 10% cholesterol at increasing [L]/[P] ratios. 
The solid lines show predictions for the resulting reaction profiles when the rate 
constants of the primary and secondary pathways are modified to include the lipid-
induced nucleation process. (e) Evolution of apparent reaction rate constants with 
increasing [L]/[P] ratios of DMPC:cholesterol vesicles containing 10% cholesterol. 
klipids/k represents in each case either k+’kn’/k+kn or k+’k2’/k+k2, where kn’, k+’, and k2’ 
are the apparent rate constants of primary nucleation, elongation, and secondary 
nucleation, respectively, in the presence of vesicles. Note the significant increase in 
k+’kn’ as compared to k+’k2’ as the [L]/[P] increases (in the yellow zone). (f) Numerical 
calculations of the reaction profiles for a solution of 2 μM Aβ42 with (blue) and 
without (black) an increase by 20-fold the rate constant of primary nucleation, kn’ (see 
Material and Methods). Inset shows t1/2 of calculated and experimental curves 
showing a maximal effect of lipids. Throughout, error bars indicate standard deviation 
among independent replicates. 
 
Figure 5. DMPC:cholesterol vesicles catalyse the formation of Aβ42 oligomers 
through heterogeneous nucleation.  (a) Log-log plot of  (0)  as a function of 
the initial concentration of Aβ42 monomers, m(0). (b) Log-log plot of α, the slope of 
acceleration  of primary nucleation, as a function of θ, the surface coverage by 
cholesterol (% of cholesterol within the membrane). A schematic representation of 
Aβ42 heterogeneous primary nucleation on the surface of DMPC:cholesterol vesicles 
is also shown. Note that heterogeneous primary nucleation occurs as a result of the 
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cooperativity in the interaction of several cholesterol molecules with Aβ42. (c) Ratio 
of the apparent primary nucleation rate constants in the absence (black) and in the 
presence (green) of DMPC:cholesterol vesicles containing 10% cholesterol at a 
[L]/[P] ratio of 50 and either in the presence or the absence of 3 molar equivalents of 
bexarotene to Aβ42. kn is the rate constant of homogeneous primary nucleation and 
kn’ is the sum of the rate constants of both, homogeneous and heterogeneous 
primary nucleation,  Kapp/K represents either kn’
app/kn or kn
app/kn. (d) Acceleration in 
the formation of the total number of oligomers generated through increasing rates of 
primary nucleation. Error bars in (a) and (b) were derived from the extrapolation of 
the data from Supplementary Figs. 1-3 and 13, respectively. Error bars in (c) 
indicate standard deviation between independent replicates. 
 
Figure 6. DMPC:cholesterol vesicles introduces a heterogeneous nucleation 
pathway in the Aβ42 aggregation process. We present a scheme showing the 
proposed model of Aβ42 aggregation in the presence of catalytic sites formed by 
DMPC:cholesterol membrane. In the presence of DMPC:cholesterol vesicles, the 
primary nucleation of Aβ42 occurs through either homogeneous nucleation, in which 
Aβ42 nuclei are formed solely from the interactions of Aβ42 monomers, or through 
heterogeneous nucleation, in which Aβ42 nuclei are formed from the interactions of 
Aβ42 monomers and lipid membranes. In either type of primary nucleation, once a 
critical number of fibrils are formed, secondary nucleation becomes the major source 





  [L]/[P] at maximal effect rsites 
0.05 400 0.05 
0.10 200 0.20 
0.15 20 0.07 
0.20 10 0.08 
 
Table 1: Estimation of the number of accessible nucleation sites, rsites, per Aβ42 
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Chemical kinetics in the absence and presence of lipid vesicles






-4 M-1 s-1 
k ≈ 1.10-2 s-1 k+≈ 3.10
6 M-1 s-1 
k2≈ 1.10
4 M-2 s-1 
Lipid vesicles in the absence 


































































vesicles, [L]/[P] = 50 
cholesterol












ld ld  + lo lo
[L]/[P] 10 20 50 1000































































Aβ42 + DMPC:cholesterol vesicles at [L]/[P] of 10 
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Aβ42 + DMPC:cholesterol vesicles (15%) at [L]/[P] of 10 

























































































































































































































































































































2 μM Aβ42 
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Model of Aβ42 aggregation in the presence of heterogeneous primary nucleation
Aβ42 monomers Aβ42 nuclei Elongating fibrils Lipid surface
kcatmax≈ 6.10
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